Patents by Inventor James F. Callahan

James F. Callahan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Calcilytic compounds
    Patent number: 6818660
    Abstract: The present invention features calcilytic compounds. “Calcilytic compounds” refer to compounds able to inhibit calcium receptor activity. Also described are the use of calcilytic compounds to inhibit calcium receptor activity and/or achieve a beneficial effect in a patient; and techniques which can be used to obtain additional calcilytic compounds.
    Type: Grant
    Filed: October 19, 2001
    Date of Patent: November 16, 2004
    Assignee: NPS Pharmaceuticals, Inc.
    Inventors: Eric G. Del Mar, Robert M. Barmore, Derek Sheehan, Bradford C. Van Wagenen, James F. Callahan, Richard M. Keenan, Nikesh R. Kotecha, Maria Amparo Lago, Linda Sue Southall, Mervyn Thompson
  • Nf-kappab inhibitors
    Publication number: 20040192943
    Abstract: The present invention provides novel compounds and methods for using them to treat diseases with aminothiophene inhibitors of IKK-&bgr; phosphorylation of I&kgr;B. In so doing these aminothiophene inhibitors block pathological activation of transcription factor NF-&kgr;B in which diseases excessive activation of NF-&kgr;B is implicated.
    Type: Application
    Filed: April 2, 2004
    Publication date: September 30, 2004
    Inventors: Zehong Wan, Joelle L. Burgess, James F. Callahan
  • Compounds
    Publication number: 20040039198
    Abstract: This invention relates to 2-pyridyl substituted diarylimidazoles which are inhibitors of the transforming growth factor, (“TGF”)-&bgr; signaling pathway, in particular, the phosphorylation of smad2 or smad3 by the type I or activin-like kinase (“ALK”)-5 receptor, methods for their preparation and their use in medicine.
    Type: Application
    Filed: May 14, 2003
    Publication date: February 26, 2004
    Inventors: Paul E. Bender, Joelle L. Burgess, James F. Callahan
  • Nf-kb inhibitors
    Publication number: 20040024047
    Abstract: The present invention provides novel compounds and methods for treating diseases with aminothiophene inhibitors of IKK-&bgr; phosphorylation of I&kgr;B.
    Type: Application
    Filed: April 10, 2003
    Publication date: February 5, 2004
    Inventors: James F. Callahan, Amy K. Roshak
  • Calcilytic compounds
    Publication number: 20040014723
    Abstract: Novel calcilytic compounds and methods of using them are provided.
    Type: Application
    Filed: April 24, 2003
    Publication date: January 22, 2004
    Inventors: Pradip Bhatnagar, William M Bryan, James F Callahan, William F Huffman
  • Calcilytic compounds
    Publication number: 20040009980
    Abstract: Novel phosphate esters compounds and methods of using them as calcilytic compounds are provided.
    Type: Application
    Filed: April 24, 2003
    Publication date: January 15, 2004
    Inventors: Pradip Bhatnagar, Joelle L. Burgess, James F. Callahan, Maria A. Lago
  • Nf-kb inhibitors
    Publication number: 20040006118
    Abstract: The present invention provides novel compounds and methods for using them to treat diseases with aminothiophene inhibitors of IKK-&bgr; phosphorylation of I&kgr;B.
    Type: Application
    Filed: April 10, 2003
    Publication date: January 8, 2004
    Inventors: James F Callahan, Amy K Roshak
  • Calcilytic compounds
    Publication number: 20030212110
    Abstract: Novel calcilytic compounds and methods of using them are provided.
    Type: Application
    Filed: January 15, 2003
    Publication date: November 13, 2003
    Inventors: Pradip K. Bhatnagar, James F. Callahan, Amparo M. Lago
  • Inhibitors of transcription factor NF-kappaB
    Publication number: 20030092771
    Abstract: The present invention provides pharmaceutical compositions of salicylanilide inhibitors of transcription factor NF-&kgr;B, and methods for treating diseases in which activation of NF-&kgr;B is implicated. More specifically, the present invention provides methods of treatment of a variety of diseases associated with NF-&kgr;B activation including inflammatory disorders; particularly rheumatoid arthritis, inflammatory bowel disease, and asthma; dermatosis, including psoriasis and atopic dermatitis; autoimmune diseases; tissue and organ rejection; Alzheimer's disease; stroke; atherosclerosis; restenosis; cancer, including Hodgkin's disease; certain viral infections, including AIDS; osteoarthritis; osteoporosis; and Ataxia Telangiestasia by administering to a patient in need thereof a compound of the present invention.
    Type: Application
    Filed: July 31, 2002
    Publication date: May 15, 2003
    Applicant: SmithKline Beecham Corporation
    Inventors: James F. Callahan, Marie C. Chabot-Fletcher
  • Calcilytic compounds
    Patent number: 6521667
    Abstract: The present invention features calcilytic compounds. “Calcilytic compounds” refer to compounds able to inhibit calcium receptor activity. Also described are the use of calcilytic compounds to inhibit calcium receptor activity and/or achieve a beneficial effect in a patient; and techniques which can be used to obtain additional calcilytic compounds.
    Type: Grant
    Filed: August 11, 1998
    Date of Patent: February 18, 2003
    Assignees: NPS Pharmaceuticals, Inc., SmithKline Beecham, PLC, SmithKline Beecham, Corp.
    Inventors: Eric G. Del Mar, Robert M. Barmore, Derek Sheehan, Bradford C. Van Wagenen, James F. Callahan, Richard M. Keenan, Nikesh R. Kotecha, Maria Amparo Lago, Linda Sue Southall, Mervyn Thompson
  • Inhibitors of transcription factor-NF-&kgr;B
    Patent number: 6492425
    Abstract: The present invention provides pharmaceutical compositions of salicylanilide inhibitors of transcription factor NF-&kgr;B, and methods for treating diseases in which activation of NF-&kgr;B is implicated. More specifically, the present invention provides methods of treatment of a variety of diseases associated with NF-&kgr;B activation including inflammatory disorders; particularly rheumatoid arthritis, inflammatory bowel disease, and asthma; dermatosis, including psoriasis and atopic dermatitis; autoimmune diseases; tissue and organ rejection; Alzheimer's disease; stroke; atherosclerosis; restenosis; cancer, including Hodgkin's disease; certain viral infections, including AIDS; osteoarthritis; osteoporosis; and Ataxia Telangiestasia by administering to a patient in need thereof a compound of the present invention.
    Type: Grant
    Filed: December 19, 2000
    Date of Patent: December 10, 2002
    Assignee: SmithKline Beecham Corporation
    Inventors: James F. Callahan, Marie C. Chabot-Fletcher
  • Triarylimidazoles
    Patent number: 6465493
    Abstract: Compounds of formula (I) or a pharmaceutically acceptable salt thereof: wherein R1, R2 and R3 are various substituent groups; and one of X1 and X2 is N or CR′, and the other is NR′ or CHR′ wherein R′ is hydrogen, OH, C1-6alkyl, or C3-7cycloalkyl; or when one of X1 and X2 is N or CR′ then the other may be S or O; and their use as pharmaceuticals.
    Type: Grant
    Filed: October 9, 2001
    Date of Patent: October 15, 2002
    Assignee: Smithkline Beecham Corporation
    Inventors: Joelle L. Burgess, James F. Callahan
  • Calcilytic compounds
    Patent number: 6432656
    Abstract: The present invention features calcilytic compounds. “calcilytic compounds” refer to compounds able to inhibit calcium receptor activity. Also described are the use of calcilytic compounds to inhibit calcium receptor activity and/or achieve a beneficial effect in a patient; and techniques which can be used to obtain additional calcilytic compounds.
    Type: Grant
    Filed: August 6, 1999
    Date of Patent: August 13, 2002
    Assignee: NPS Pharmaceuticals, Inc.
    Inventors: Eric G. Del Mar, Robert M. Barmore, Derek Sheehan, Bradford C. Van Wagenen, James F. Callahan, Richard M. Keenan, Nikesh R. Kotecha, Maria Amparo Lago, Linda Sue Southall, Mervyn Thompson
  • Calcilytic compounds
    Publication number: 20020099220
    Abstract: The present invention features calcilytic compounds. “Calcilytic compounds” refer to compounds able to inhibit calcium receptor activity. Also described are the use of calcilytic compounds to inhibit calcium receptor activity and/or achieve a beneficial effect in a patient; and techniques which can be used to obtain additional calcilytic compounds.
    Type: Application
    Filed: October 19, 2001
    Publication date: July 25, 2002
    Applicant: NPS Pharmaceuticals, Inc.
    Inventors: Eric G. Del Mar, Robert M. Barmore, Derek Sheehan, Bradford C. Van Wagenen, James F. Callahan, Richard M. Keenan, Nikesh R. Kotecha, Maria Amparo Lago, Linda Sue Southall, Mervyn Thompson
  • Method of using calcilytic compounds
    Patent number: 6022894
    Abstract: The present invention features calcilytic compounds. "Calcilytic compounds" refer to compounds able to inhibit calcium receptor activity. Also described are the use of calcilytic compounds to inhibit calcium receptor activity and/or achieve a beneficial effect in a patient; and techniques which can be used to obtain additional calcilytic compounds.
    Type: Grant
    Filed: April 4, 1997
    Date of Patent: February 8, 2000
    Assignees: NPS Pharmaceuticals, Inc., SmithKline Beecham, Corp., SmithKline Beecham, PLC
    Inventors: Eric G. Del Mar, Robert M. Barmore, Derek Sheehan, Bradford C. Van Wagenen, James F. Callahan, Richard M. Keenan, Nikesh R. Kotecha, Maria Amparo Lago, Linda Sue Southall, Mervyn Thompson
  • 1,4 Diazocines as fibrinogen antagonists
    Patent number: 5539104
    Abstract: This invention relates to a method of inhibiting platelet aggregation using 1,4-diazocine compounds which are mimics of the peptide sequence Arg--Gly--Asp.
    Type: Grant
    Filed: April 29, 1994
    Date of Patent: July 23, 1996
    Assignee: SmithKline Beecham Corp.
    Inventors: James F. Callahan, William F. Huffman
  • .gamma.-turn peptidomimetics as fibrinogen antagonists
    Patent number: 5470849
    Abstract: This invention relates to a method of inhibiting platelet aggregation, and compounds which are mimics of the peptide sequence Arg-Gly-Asp.
    Type: Grant
    Filed: April 30, 1993
    Date of Patent: November 28, 1995
    Assignee: SmithKline Beecham Corp.
    Inventors: James F. Callahan, William F. Huffman
  • HIV protease inhibitors
    Patent number: 5438118
    Abstract: Peptide mimics, having a constrained peptide backbone conformation, are HIV protease inhibitors. A compound of this invention is, for example, 3-Benzyl-5(alaninyl-1-aminoethyl)-2,3,6,7-tetrahydro-N-azepinyl-2-propiony l-valinyl-valinyl methyl ester.
    Type: Grant
    Filed: July 26, 1993
    Date of Patent: August 1, 1995
    Assignee: SmithKline Beechman Corp.
    Inventors: James F. Callahan, William F. Huffman, Michael L. Moore, Kenneth A. Newlander
  • Intermediates for preparing 1,6-dicarba-vasopressin compounds
    Patent number: 4908475
    Abstract: New compounds which have potent V.sub.2 -vasopressin antagonistic activity are prepared by a 1,6-cyclization using peptide bond formation. The structures of the compounds are characterized by a Pas.sup.1,6 or Tas.sup.1,6 cyclized unit. Also a chiral synthesis of the optically pure Pas intermediates is described.
    Type: Grant
    Filed: May 9, 1988
    Date of Patent: March 13, 1990
    Assignee: SmithKline Beckman Corporation
    Inventors: James F. Callahan, William F. Huffman, Kenneth A. Newlander, Nelson C. F. Yim
  • Intermediates for preparing 1,6-dicarba-vasopressin compounds
    Patent number: 4810778
    Abstract: New compounds which have potent V.sub.2 -vasopressin antagonistic activity are prepared by a 1,6-cyclization using peptide bond formation. The structures of the compounds are characterized by the Pas.sup.1,6 or Tas.sup.1,6 cyclized unit. Also a chiral synthesis of the optically pure Pas intermediates is described.
    Type: Grant
    Filed: May 9, 1988
    Date of Patent: March 7, 1989
    Assignee: SmithKline Beckman Corporation
    Inventors: James F. Callahan, William F. Huffman, Kenneth A. Newlander, Nelson C. F. Yim